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Although the literature on the contribution of DHA and arachidonic acid (ARA) to funda-
mental metabolic functions in brain, immune and cardiovascular systems is extensive, there
is a lack of consensus on the need for explicit recommendations on dietary intake for both
DHA and ARA during the early years of life. This review takes a public health perspective
with the objective of ensuring that recommendations protect the most vulnerable children
worldwide. Most studies on the effects of DHA and ARA in early life have been undertaken
in high-income countries and this is reﬂected in policy recommendations. Although breast
milk is considered the gold standard and always contains DHA and ARA, there are propo-
sals that infant formulas, especially follow-on formulas, do not need to be supplemented
with these fatty acids. Complementary foods frequently have low concentrations of ARA
and DHA and this is most signiﬁcant in low-income countries where availability is also lim-
ited. Recent evidence shows that in developing countries, intakes of DHA and ARA during
the age period 6–36 months are low and this relates to low national income. It is concluded
that a continuum of DHA and ARA intake needs to be maintained during early life, a crit-
ical period of infant growth and development. For both infant and follow-on formulas,
DHA and ARA should be mandatory at levels that are equivalent to breast milk. An
optional recommendation may be limited to countries that can demonstrate evidence of
adequate intakes of DHA and ARA during early life.
DHA: Arachidonic acid: Dietary intakes: Infants and children: Public health
For the past two decades, there has been considerable
interest in the roles of long-chain PUFA in infant growth
and development(1,2). However, despite an extensive lit-
erature describing their contribution to fundamental
metabolic functions in brain, immune and cardiovascular
systems there has been a lack of consensus amongst the
policy-making community on the need for explicit
recommendations on dietary intake of DHA and arachi-
donic acid (ARA) during the early years of life(3,4). Most
recently the European Food Safety Authority Panel on
Dietetic Products, Nutrition and Allergies concluded
that ARA (20 : 4 n-6) is not necessary in terms of infant
formulas when DHA (22 : 6 n-3) is present(3). However,
responses to this opinion from infant nutrition scientists
and clinicians suggest that there is a lack of evidence to
support this view and moreover it may be harmful to pro-
vide dietary DHA without adequate levels of ARA(5).
A fundamental issue is that most studies have been
performed in high-income countries and there is very lit-
tle research data on the most vulnerable infants living in
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low-income communities. Moreover, current policy
recommendations have tended to be driven by data
from randomised controlled trials (RCT) undertaken in
institutions located in high-income countries. Policymakers
have a responsibility to protect the most vulnerable and
this may require balancing the evidence from RCT with
observational data obtained from real-world settings.
The present paper takes a public health approach to the
assessment of the need for ARA and DHA in early life
with the aim of providing a pragmatic and coherent way
forward that may more effectively serve the needs of the
most vulnerable infants and young children.
The benchmark
The WHO recommends that mothers worldwide exclu-
sively breastfeed infants for the child’s ﬁrst 6 months to
achieve optimal growth, development and health.
Thereafter, they should be given nutritious complemen-
tary foods and continue breastfeeding up to age 2 years
or beyond(6). It is recognised that additional nutrient-
dense complementary foods (liquid and solid) are
required following the exclusive breastfeeding period to
prevent undernutrition and stunting in the childhood
population(7).
Human milk has several compositional components
that make it unique with a potent example being the con-
tinual presence of signiﬁcant quantities of DHA and
ARA. In contrast, only trace amounts may be found in
cow’s milk, goat milk, soya milk and rice milk and there-
fore the level of availability in human milk, as opposed
to other animal and plant milks, is highly indicative of
their essentiality for human infants. Moreover, there
are well-documented evolutionary changes that have
led to the development of transport mechanisms for
both fatty acids to cross the placenta from the mother
to the fetus during pregnancy(8) and for the fatty acids
to be released from maternal lipid stores
and transported to the breast during lactation(9). Both
of these evolutionary mechanisms enhance the delivery
of DHA and ARA to the fetus during the prenatal period
and to the infant post-birth, a process frequently
described as biomagniﬁcation(10).
Challenging evolution by proposing that if infants are
not being breastfed, they should receive nutritional pro-
ducts that do not contain both DHA and ARA, is a high-
risk strategy(11). With the current benchmark for early
nutrition being the composition of breast milk, which
contains both ARA and DHA, any discussions that con-
sider a nutritional product that is devoid of these fatty
acids need to reﬂect carefully on the risks and potential
harm that may occur as an unintended consequence of
the deviation from the evolved nutritional composition
of human milk.
Human milk
In 2007, Brenna et al. published data from sixty-ﬁve stud-
ies, 2474 women and thirty-three countries and reported
that the mean concentration of DHA in breast milk (by
weight per cent (wt %) of total fatty acids) was 0·32 %
(range 0·06–1·4 %) and the mean concentration of
ARA was 0·47 % (range 0·24–1·0 %)(12). In 2016, Fu
et al. provided data on seventy-eight studies from forty-
one countries and 4163 breast milk samples and reported
that the worldwide mean levels of DHA and ARA in
breast milk were 0·37 (SD 0·11) % and 0·55 (SD 0·14) %(13).
Both studies showed that the ARA content of breast
milk is relatively consistent compared with DHA, the lat-
ter being particularly inﬂuenced by maternal diet. The
levels of DHA were particularly low in populations
with the greatest poverty; 0·06 % DHA in Pakistan,
Northern Sudan, and 0·10 % DHA in Southern Sudan.
Applying the WHO recommendation on exclusive
breastfeeding for 6 months, it is estimated that at 6
months, infants will be receiving approximately 190
mg/d ARA and 130 mg/d DHA, based on a breast
milk intake of 850 ml/d and the reported mean concen-
trations of DHA and ARA in human milk. An infant
receiving a formula without supplemented DHA and
ARA will clearly have zero consumption from milk
feeds during this time.
Complementary foods
Complementary foods tend to have low concentrations
of ARA and DHA and their contribution to dietary
intakes compared with breast milk is low, and this is evi-
dent in both high-(14) and low-income countries(15). In
Germany, dietary intake of ARA and DHA at 9 months
was 24 and 28 mg/d respectively at 9 months compared
with 72 and 47 mg/d at 6 months when breastfeeding
was more prevalent(14). Similarly, in Gambia intakes of
ARA and DHA at 24 months were both 10 mg/d com-
pared with 90 and 110 mg/d during the period of 0–6
months(15). In low-income countries, it is common prac-
tice for weaning infants to receive food from the family
bowl, which is most commonly of plant origin and has
low ARA and DHA content(15). In a recent publication,
dietary intake of ARA and DHA at the population level,
was strongly related to the economic status of the coun-
try (Table 1)(16). The analysis was based on food con-
sumption data originally collected by the Food and
Agriculture Organisation of the United Nations and by
utilising food composition tables, the per capita dietary
intakes of DHA and ARA were estimated for 175 coun-
tries worldwide, with forty-seven classiﬁed as developed
and 128 as developing. This analysis demonstrated that
intakes of both fatty acids varied signiﬁcantly in relation
to the gross national income of the country, with low-
income countries having intakes of DHA and ARA
which were approximately 20–25 % of that of high-
income countries(16) (Table 1)
Estimates were also made of DHA and ARA intakes
during the age period of 6–36 months. This analysis esti-
mated intakes of DHA and ARA from breast milk and
complementary foods with median duration of breast-
feeding, mean concentration of DHA and ARA in breast
milk and mean intakes of breast milk intakes as factors
S. Forsyth et al.2
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within the calculation(17). The data showed that the com-
bined intake of ARA and DHA from both breast milk
and complementary foods was lower than previous
recommendations(4) and signiﬁcantly inﬂuenced by
socio-economic status of the country (Table 2). The
data also clearly demonstrated that DHA and ARA
intake from complementary foods were exceptionally
low in poor-resource countries (Table 3)(17).
In the low-income countries, the predominant nutri-
tional source of DHA and ARA during the second and
third years of life was breast milk, reﬂecting the limited
availability of complementary food sources for these
fatty acids. However, beyond the age of 6 months, breast
milk does not have the nutritional density to meet the
increasing energy and nutrient demands of the growing
infant, and failure to provide adequate nutritious com-
plementary foods places the infant at risk of developing
undernutrition and stunting(7). The intake of ARA and
DHA from complementary foods was particularly low
in Nepal, Bangladesh, Ethiopia and Rwanda(16,17).
Birth rate is several-fold higher in low-income coun-
tries compared with more afﬂuent populations and this
further increases the overall prevalence of long-chain
PUFA (LCPUFA) dietary deﬁciency in these countries.
The recent analyses included twenty-ﬁve low-income
countries, which involved a total population of 644 mil-
lion, and an average birth rate of thirty-four births per
1000 population. It is estimated that each year in this
cohort of countries, approximately twenty-two million
infants are born and they are at signiﬁcant risk of
LCPUFA insufﬁciency (16,17).
Importance of a continuum of DHA and arachidonic
acid intake during early life
In 1992, seminal work by Manuela Martinez demon-
strated that during the latter part of pregnancy and dur-
ing the ﬁrst 2 years of life there is a rapid accumulation of
both DHA and ARA in the developing brain(18). Shortly
after this publication there were two papers showing that
the DHA content of the infant brain was higher in
breastfed infants compared with infants who had
received infant formulas that were devoid of both
DHA and ARA(19,20). It was subsequently shown in an
RCT that infants receiving a formula with added DHA
and ARA had higher blood levels of DHA and ARA
during the ﬁrst year of life compared with infants who
received a formula that was not supplemented with
these fatty acids(21). These data clearly highlight that diet-
ary intake of DHA and ARA signiﬁcantly inﬂuence fatty
acid status at this critical period of development and a
continuum of DHA and ARA intake during early life
should be a key nutritional objective.
It is also evident that after 6 months of age the balance
between breast milk intake and complementary feeding,
is critical. Although breast milk is an important source
of DHA and ARA the volume of breast milk intake
will decline to allow capacity for high-density comple-
mentary foods, and unless these foods contain adequate
levels of ARA and DHA there will be a depletion in
these fatty acid levels(21). It is therefore important that
not only should complementary foods in developed and
developing countries be commenced around the age of
6 months, but also the continuum of DHA and ARA
intake needs to be maintained. This can be achieved by
ensuring that complementary foods (both liquid and
solid), contain these fatty acids.
Inter-dependency between DHA and arachidonic acid
There is a biochemical interdependency between DHA
and ARA as they share the same metabolic pathway
that enables desaturation and elongation of precursor
fatty acids. Studies have shown that the endogenous syn-
thesis of both DHA and ARA in early life is insufﬁcient
to meet metabolic requirements and that blood and tissue
concentrations decrease rapidly after birth if exogenous
Table 1. Per capita estimated daily intakes of arachidonic acid (ARA)
and DHA by gross national income (GNI) of country in 174 countries(16)
GNI (n) countries
Median (range) daily
ARA intake** (mg/d){
Median daily DHA
intake** (mg/d){
High income (42) 216·4 (53–476) 174·7 (62–638)
Upper middle (50) 154·0 (71–316) 107·8 (28–1200)
Lower middle (53) 86·7 (29–267) 118·5 (12–530)
Low income (29) 39·1 (17–180) 41·3 (6–383)
Total (174) 135·1 (17–476) 118·4 (6–1200)
Kruskal–Wallis H test. **P < 0·001.
{ The Kruskal–Wallis H test is used to determine whether there are any
statistically signiﬁcant differences in distribution of key outcome variables
between three or more variable groups.
Table 2. Estimation of arachidonic acid (ARA) and DHA dietary intakes
from breast milk (BM) and complementary foods (food) in 6–36months
old children living in seventy-six developing countries (17)
Gross
national
income
Median (range) daily ARA
intake BM/food (mg/d)
Median (range) daily DHA
intake BM/food (mg/d)
Upper middle 68·3 (38–137) 42·9 (14–371
Lower middle 63·1 (49–95) 51·5 (24–120)
Low income 61·5 (50–92) 50·1 (28–121)
Total 63·7 (38–137) 48·8 (14–371)
Table 3. Estimation of arachidonic acid (ARA) and DHA dietary
intakes from complementary foods in 6–36 months old children
living in seventy-six developing countries (17)
Gross
national
income
Median (range)
daily ARA intake
complementary food
(no breast milk)** (mg/d)
Median (range)
daily DHA intake
complementary food
(no breast milk)* (mg/d)
Upper middle 34·6 (21–67) 23·7 (10–175)
Lower middle 19·1 (5–61) 16·5 (3–80)
Low income 8·9 (1–22) 9·6 (0·7–65)
Total 17·9 (1–67) 14·6 (0·7–175)
Kruskal–Wallis H test. **P < 0·001, *P < 0·05.
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supplies are not adequate(22–24). It is also important to
note the data from animal and human studies that have
shown that alteration of the intake of either DHA or
ARA can signiﬁcantly inﬂuence the endogenous synthe-
sis of the other. For example, when pregnant rats were
fed marine oil with high EPA/DHA and a limited supply
of ARA, ARA levels in brain phospholipids in the off-
spring were severely decreased by nearly 50 % compared
with controls(25). Similar effects, a 25 % decrease in ARA
blood levels, have been noted in human infants when for-
mulas were supplemented with DHA but not ARA. The
balance between DHA and ARA was signiﬁcantly differ-
ent from that of breast milk(26). This evidence indicates
that an imbalance of the DHA and ARA content of
infant formula should not be recommended without
clear evidence of its short- and long-term safety.
Scientiﬁc evidence
There is a wealth of evidence from experimental and ani-
mal studies that DHA and ARA have critical functions
in human metabolism. It is evident that DHA has a
key role in visual and cognitive development(27) and
that ARA is a key intermediary in the synthesis of leuko-
trienes, prostacyclines, thromboxanes and PG that have
important roles in brain, immune and cardiovascular
function(28). Translating this scientiﬁc evidence into clin-
ical beneﬁt as evidenced by RCT has been challenging;
however, current evidence indicates that cognitive func-
tions in the ﬁelds of attention control, information pro-
cessing and problem solving are enhanced in
intervention groups(29). A major concern is that the
RCT have almost entirely been undertaken in high-
income countries, with most publications being from
institutions in North America, Europe and Australia.
Undertaking studies in populations that are reasonably
endowed with DHA and ARA will undoubtedly impact
on the outcomes of the study and this is reﬂected in the
conclusions of systematic reviews. The relevance of the
current clinical studies and their related systematic
reviews needs to be considered in a context of a marked
global variation in dietary intakes of DHA and ARA
with the lowest dietary intakes being in the poorest
countries(16,17).
Clinical intervention studies tend to take place in the
context of a relatively, well-deﬁned biological environ-
ment with a narrow variation in individual responses,
whereas public health interventions take cognisance of
the wide spectrum of social difference in the study popu-
lation. Long-term outcomes are particularly important in
studies that are attempting to relate nutrition in early life
to health in later childhood and adulthood; however, in
longitudinal RCT, data on outcome measures are fre-
quently subject to attrition rates that undermine the
integrity of the randomisation model. While RCT, not-
ably cluster RCT, can be designed to evaluate some com-
plex public health programmes, often they are not
feasible because of the practical or resource constraints
and consequently well-conducted RCT are relatively
rare in public health.
Public health perspective
Public health focuses on promoting or protecting
health in communities and national populations, and
an overarching priority is to reduce health inequalities.
The public health considerations of a speciﬁc health
issue within a population will generally include the per-
ceived magnitude and importance of the problem, the
potential effectiveness and harms of an intervention,
the feasibility of its implementation, and its political
and public acceptability(30).
If these factors are considered in a public health
approach to DHA and ARA intakes within a popu-
lation, it is likely to be concluded that the evidence
indicates that the perceived issue is of considerable mag-
nitude, involving many countries and with many millions
of infants and young children receiving low dietary
intakes of DHA and ARA. The intervention of DHA
and ARA supplementation of infant and follow-on for-
mulas has already been tried and tested in many millions
of infants over the past two decades and no regulatory
body has reported any concerns regarding potential
harm; the implementation is feasible as there are already
formulas and complementary foods that are available
and widely distributed in the public domain, especially
in high-income countries. Finally there is increasing
awareness within the general public of the potential
health beneﬁts of LCPUFA, especially DHA, at different
stages of the life cycle. In addition, most governments are
committed to reducing health inequalities and the avail-
able evidence clearly indicates that dietary intakes of
DHA and ARA are signiﬁcantly inﬂuenced by socio-
economic factors within the population.
Although infants and their families living in medium
to low-income countries are at greatest risk of dietary
deﬁciencies of ARA and DHA in early life, shorter dur-
ation of breastfeeding and the early introduction of low
content of ARA and DHA in complementary foods
can decrease dietary intake of ARA and DHA in infants
living in more afﬂuent communities. It is therefore evi-
dent that global policy recommendations need to be
inclusive of all countries.
Conclusions
Relating early life nutritional interventions to later life
health outcomes is always going to be challenging and
all research methods will have their limitations. There
is a real concern that null RCT of LCPUFA supplemen-
tation may be misinterpreted to indicate that low dietary
intake of DHA and ARA will be of no consequence to
even the most vulnerable infants. Recent evidence indi-
cates that a high proportion of the global childhood
population may be at risk of LCPUFA deﬁciency in
early life(16,17).
It is important that the body of research available to
policymakers reﬂects the diversity of the populations
being considered and that studies need to be inclusive
and focus on those individuals and communities that
are at greatest risk. In some settings, observational
S. Forsyth et al.4
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studies may represent the most feasible and appropriate
study designs for identifying ‘at risk’ populations and
evaluating the public health interventions.
The principal objective of recommendations on diet-
ary DHA and ARA in early life should be to provide a
safety net for the most vulnerable infants worldwide. In
relation to infant formulas and follow-on formulas, the
availability of DHA and ARA should be mandatory to
protect infants who do not receive adequate supplies of
breast milk and to prevent further nutritional inequality
between high- and low-income countries. Levels of
DHA and ARA in infant formulas and follow-on formu-
las should equate to median levels of DHA and ARA in
breast milk and a minimum level needs to be determined.
For countries that can clearly evidence that infants and
young children consume adequate intakes of DHA and
ARA during early life, an optional recommendation
for these countries may be considered.
Financial Support
None.
Conﬂicts of Interest
S. F. undertakes consultancy work for DSM Nutritional
Products. S. G. and N. S. are employees of DSM
Nutritional Products and the company produces ARA
and DHA.
Authorship
All authors were involved in the planning and writing of
the paper.
References
1. Swanson D, Block R & Mousa SA (2012) Omega-3 fatty
acids EPA and DHA: health beneﬁts throughout life. Adv
Nutr 3, 1–7.
2. Calder PC (2015) Functional roles of fatty acids and their
effects on human health. J Parenter Enteral Nutr 39,
Suppl. 1, 18S–32S.
3. European Food Safety Authority. Panel on Dietetic
Products, Nutrition and Allergies (NDA) (2014) Scientiﬁc
opinion on the essential composition of infant and
follow-on formulae. EFSA J 12, 3760.
4. Food and Agriculture Organization of the United Nations
(2010) Fats and fatty acids in human nutrition Report of an
expert consultation. 10−14 November 2008, Geneva. FAO
Food and Nutrition Paper 91. ISBN 978-92-5-106733-8.
Rome. http://www.fao.org/docrep/013/i1953e/i1953e00.pdf
(accessed December 2016).
5. Crawford MA, Wang Y, Forsyth S et al. (2015) The
European Food Safety Authority recommendation for
polyunsaturated fatty acid composition of infant formula
overrules breast milk, puts infants at risk, and should be
revised. Prostaglandins Leukot Essent Fatty Acids 102–
103, 1–3.
6. World Health Organization (2002) Nutrient adequacy of
exclusive breastfeeding for the term infant during the ﬁrst
six months of life. http://www.who.int/nutrition/publica-
tions/infantfeeding/9241562110/en/
7. World Health Organisation (2001) Guiding principles
for complementary feeding of the breastfed child. http://
www.who.int/nutrition/publications/guiding_principles_
compfeeding_breastfed.pdf
8. Lauritzen L & Carlson SE (2011) Maternal fatty acid status
during pregnancy and lactation and relation to newborn
and infant status. Matern Child Nutr 7, Suppl. 2, 41–58.
9. Demmelmair H, Kuhn A, Dokoupil K et al. (2016) Human
lactation: oxidation and maternal transfer of dietary (13)
C-labelled α-linolenic acid into human milk. Isotopes
Environ Health Stud 52, 270–280.
10. Kuipers RS, Luxwolda MF, Janneke Dijck-Brouwer DA
et al. (2011) Intrauterine, postpartum and adult relation-
ships between arachidonic acid (ARA) and docosahexae-
noic acid (DHA). PLEFA 85, 245–252.
11. Brenna JT (2016) Arachidonic acid needed in infant formula
when docosahexaenoic acid is present.Nutr Rev 74, 329–336.
12. Brenna JT, Varamini B, Jensen DA et al. (2007)
Docosahexaenoic and arachidonic acid concentrations in
human breast milk worldwide. Am J Clin Nutr 85, 1457–
1464.
13. Fu Y, Liu X, Zhou B et al. (2016) An updated review of
worldwide levels of docosahexaenoic and arachidonic
acid in human breast milk by region. Public Health Nutr
19, 2675–2687.
14. Schwartz J, Dube K, Alexy U et al. (2010) PUFA and
LC-PUFA intake during the ﬁrst year of life: can dietary
practice achieve a guideline diet? Eur J Clin Nutr 64, 124–130.
15. Prentice AM & Paul AA (2000) Fat and energy needs of
children in developing countries. Am J Clin Nutr 72,
1253S–1265S.
16. Forsyth S, Gautier S & Salem N Jr (2016) Global estimates
of dietary intake of docosahexaenoic acid and arachidonic
acid in developing and developed countries. Ann Nutr
Metab 68, 258–267.
17. Forsyth S, Gautier S & Salem N Jr (2016) Estimated diet-
ary intakes of arachidonic acid and docosahexaenoic acid
in infants and young children living in developing coun-
tries. Ann Nutr Metab 69, 64–74.
18. Martinez M (1992) Tissue levels of polyunsaturated fatty
acids during early human development. J Pediatr 120,
S129–S138.
19. Makrides M, Neumann Byard RW, Simmer K et al. (1994)
Fatty acid composition of brain, retina, and erythrocytes in
breast- and formula-fed infants. Am J Clin Nutr 60, 89–94.
20. Farquharson J, Jamieson EC, Abbasi KA et al. (1995)
Effect of diet on the fatty acid composition of the major
phospholipids of infant cerebral cortex. Arch Dis Child
72, 198–203.
21. Birch EE, Castañeda YS, Wheaton DH et al. (2005) Visual
maturation of term infants fed long-chain polyunsaturated
fatty acid-supplemented or control formula for 12 mo. Am
J Clin Nutr 81, 871–879.
22. Brenna JT, Salem N Jr, Sinclair AJ et al. (2009) α-Linolenic
acid supplementation and conversion to n-3 long chain
polyunsaturated fatty acids in humans. Prost Leuk
Essential Fatty Acids 80, 85–91.
23. Salem N Jr, Wegher B, Mena P et al. (1996) Arachidonic
and docosahexaenoic acids are biosynthesized from their
18-carbon precursors in human infants. Proc Natl Acad
Sci USA 93, 49–54.
24. Carnielli VP, Simonato M, Verlato G et al. (2007)
Synthesis of long-chain polyunsaturated fatty acids in
Public health and DHA and ARA in early life 5
P
ro
ce
ed
in
gs
o
f
th
e
N
u
tr
it
io
n
So
ci
et
y
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0029665117000313
Downloaded from https:/www.cambridge.org/core. Dundee University Library, on 21 Mar 2017 at 16:50:56, subject to the Cambridge Core terms of use, available at
preterm newborns fed formula with long-chain polyunsat-
urated fatty acids. Am J Clin Nutr 86, 1323–1330.
25. Yonekubo A, Honda S, Okano M et al. (1993) Dietary ﬁsh
oil alters rat milk composition and liver and brain fatty acid
composition of fetal and neonatal rats. J Nutr 123, 1703–
1708.
26. Makrides M, Gibson RA, Udell T et al. (2005)
Supplementation of infant formula with long-chain polyun-
saturated fatty acids does not inﬂuence the growth of term
infants. Am J Clin Nutr 81, 1094–1101.
27. Koletzko B, Boey CC, Campoy C et al. (2014) Current infor-
mation and Asian perspectives on long-chain polyunsaturated
fatty acids in pregnancy, lactation, and infancy: systematic
review and practice recommendations from an early nutrition
academy workshop. Ann Nutr Metab 65, 49–80.
28. Hadley KB, Ryan AS, Forsyth S et al. (2016) The es-
sentiality of arachidonic acid in infant development.
Nutrients 8, 216.
29. Koletzko B, Carlson SC & van Goudoever JB (2015)
Should infant formula provide both omega-3 DHA and
omega-6 arachidonic acid? Ann Nutr Metab 66, 137–138.
30. Rychetnik L, Frommer M, Hawe P et al. (2002) Criteria
for evaluating evidence on public health interventions.
J Epidemiol Commun Health 56, 119–127.
S. Forsyth et al.6
P
ro
ce
ed
in
gs
o
f
th
e
N
u
tr
it
io
n
So
ci
et
y
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0029665117000313
Downloaded from https:/www.cambridge.org/core. Dundee University Library, on 21 Mar 2017 at 16:50:56, subject to the Cambridge Core terms of use, available at
